Mouse CD20 expression and function.

CD20 plays a role in human B cell proliferation and is an effective target for immunotherapy. In this study, mouse CD20 expression and biochemistry were assessed for the first time using a new panel of CD20-specific mAb, with CD20 function assessed using CD20-deficient (CD20(-/-)) mice. CD20 expression was B cell restricted and was initiated during late pre-B cell development. The frequency and density of CD20 expression increased during B cell maturation in the bone marrow, with a subpopulation of transitional IgM(hi) B cells expressing higher CD20 levels than the majority of mature recirculating B cells. Transitional T1 B cells in the spleen also expressed high CD20 levels, providing a useful new marker for this B cell subset. In CD20(-/-) mice, immature and mature B cell IgM expression was approximately 20-30% lower relative to B cells from wild-type littermates. In addition, CD19-induced intracellular calcium responses were significantly reduced in CD20(-/-) B cells, with a less dramatic effect on IgM-induced responses. These results reveal a role for CD20 in transmembrane Ca(2+) movement in mouse primary B cells that complements previous results obtained using human CD20 cDNA-transfected cell lines. Otherwise, B cell development, tissue localization, signal transduction, proliferation, T cell-dependent antibody responses and affinity maturation were normal in CD20(-/-) mice. Thus, mouse and human CD20 share similar patterns of expression and function. These studies thereby provide an animal model for studying CD20 function in vivo and the molecular mechanisms that influence anti-CD20 immunotherapy.

[1]  E. Génot,et al.  Hyperphosphorylation of CD20 in hairy cells. Alteration by low molecular weight B cell growth factor and IFN-alpha. , 1991, Journal of immunology.

[2]  T. Tedder,et al.  Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. , 2001, Genomics.

[3]  G. Pinkus,et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.

[4]  B. Koller,et al.  Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Neuberger,et al.  Mice carrying a CD20 gene disruption , 1998, Immunogenetics.

[6]  P. Sideras,et al.  B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor–Derived Signals , 1999, The Journal of experimental medicine.

[7]  R. Frizzell,et al.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes , 1993, The Journal of cell biology.

[8]  M. Kanzaki,et al.  Activation of a Calcium-permeable Cation Channel CD20 Expressed in Balb/c 3T3 Cells by Insulin-like Growth Factor-I* , 1997, The Journal of Biological Chemistry.

[9]  I. Stamenkovic,et al.  Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein , 1988, The Journal of experimental medicine.

[10]  L. Nadler,et al.  Expression of cell surface markers after human B lymphocyte activation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Tedder,et al.  Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. , 1988, The Journal of biological chemistry.

[12]  E. Clark,et al.  Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. , 1987, Journal of immunology.

[13]  A. Freedman,et al.  The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. , 1985, Journal of immunology.

[14]  J. Golay,et al.  Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies. , 1987, Immunology.

[15]  G. Kelsoe,et al.  In Situ Studies of the Primary Immune Response to (4-Hydroxy-3-Nitrophenyl)Acetyl. V. Affinity Maturation Develops in Two Stages of Clonal Selection , 1998, The Journal of experimental medicine.

[16]  E. Smeland,et al.  The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Kelsoe,et al.  In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations , 1991, The Journal of experimental medicine.

[18]  A. Forsgren,et al.  Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes , 1986, European journal of immunology.

[19]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[20]  M. Fujimoto,et al.  Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. , 1999, Immunity.

[21]  M. Holder,et al.  Engagement of CD20 suppresses apoptosis in germinal center B cells , 1995, European journal of immunology.

[22]  B. Koller,et al.  Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. , 1995, Immunity.

[23]  P. Chu,et al.  Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study , 2002, Leukemia & lymphoma.

[24]  G. Schieven,et al.  Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.

[25]  J. Daley,et al.  Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development , 1994, Molecular and cellular biology.

[26]  E. Clark,et al.  The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.

[27]  G. Schieven,et al.  Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. , 1993, Journal of immunology.

[28]  M. Kaminski,et al.  Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.

[29]  R. Al-Daccak,et al.  CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines , 1999, European journal of immunology.

[30]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[31]  K. Rajewsky,et al.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. , 1979, Journal of immunology.

[32]  T. Tedder,et al.  Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. , 1991, Journal of immunology.

[33]  T. Tedder,et al.  Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). , 1989, Journal of immunology.

[34]  M. Kanzaki,et al.  Expression of Calcium-permeable Cation Channel CD20 Accelerates Progression through the G1 Phase in Balb/c 3T3 Cells(*) , 1995, The Journal of Biological Chemistry.

[35]  D. Maloney,et al.  Clinical status and optimal use of rituximab for B-cell lymphomas. , 1998, Oncology.

[36]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[37]  E. Clark,et al.  Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. , 1989, The Journal of biological chemistry.

[38]  M. Kaminski,et al.  Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Kanzaki,et al.  Activation of the Calcium-permeable Cation Channel CD20 by α Subunits of the Gi Protein* , 1997, The Journal of Biological Chemistry.

[40]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[41]  S. Levy,et al.  The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.

[42]  E. Génot,et al.  Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. Evidence for involvement of calcium/calmodulin-dependent protein kinase II. , 1993, Journal of immunology.

[43]  M. Introna,et al.  Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. , 1992, Journal of immunology.

[44]  J. Ledbetter,et al.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.

[45]  G. Adams,et al.  Monoclonal antibody therapy for cancer. , 2003, Annual review of medicine.

[46]  M. Fujimoto,et al.  CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. , 1999, Journal of immunology.

[47]  H. Saito,et al.  Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Köhler,et al.  Transitional B cells are the target of negative selection in the B cell compartment , 1995, The Journal of experimental medicine.

[49]  D. Morris,et al.  Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. , 1991, Journal of immunology.

[50]  T. Tedder,et al.  Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. , 1988, Molecular immunology.

[51]  J. Brown,et al.  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.

[52]  S. A. Bush,et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Eary Radioimmunotherapy of B-cell lymphoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  E. Clark,et al.  Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Adler,et al.  Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. , 1988, Journal of immunology.